

21 Mar 2021 |

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast version of Five Must-Know Things, hear about new results for Lilly in Alzheimer's, a US delay for AbbVie, progress for Zolgensma in the UK, challenges for AstraZeneca's coronavirus vaccine, and a *Scrip* roundtable on industry lessons from the pandemic.

Join us for an audio catch-up on the major events in the biopharma industry in the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 19 March 2021, including: new results for Lilly in Alzheimer's; a US delay for AbbVie; progress for Zolgensma in the UK; challenges for AstraZeneca's coronavirus vaccine; and a *Scrip* roundtable on lessons from the pandemic.

These and all other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#) and [TuneIn](#) - and also now on [Spotify Podcasts](#) - and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Lilly's New Anti-Amyloid Play Hinges On Tau Bet](#)" - Scrip, 15 Mar, 2021.)

(Also see "[AbbVie's Rinvoq Delay By US FDA Could Foreshadow More Trouble For JAKs](#)" - Scrip, 17 Mar, 2021.)

(Also see "[Novartis Steers Zolgensma Towards Commercial Success In Europe](#)" - Scrip, 12 Mar, 2021.)

(Also see "[AstraZeneca's COVID-19 Vaccine PR Nightmare Won't Faze Investors](#)" - Scrip, 16 Mar, 2021.)

(Also see "[Pandemic Perspectives: R&D Lessons Learned From The COVID Year](#)" - Scrip, 17 Mar,

2021.)

[Click here to explore this interactive content online](#) 